Navigation Links
Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
Date:10/26/2009

WALTHAM, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Psoriasis finds that, among the TNF-alpha inhibitors, Amgen/Pfizer/Takeda's Enbrel maintained its market dominance in 2008 but Abbott/Eisai's Humira will emerge as the psoriasis market leader in 2018 with blockbuster sales of $1.3 billion. The report also finds that Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab -- both of which belong to the interleukin inhibitor drug class -- will together account for almost one-quarter of the psoriasis market in 2018. Briakinumab is the most promising emerging agent in the psoriasis market, according to the report.

"Briakinumab is expected to launch in early 2011 and we forecast that its sales will exceed $550 million in 2018," said Decision Resources Analyst Irene Koulinska, M.D. "In contrast, none of the oral agents in development such as Isotechnika Pharma's voclosporin and Celgene's apremilast seem to offer major advantages over marketed systemic therapies, and their potential launches are not expected to have a notable impact on the psoriasis market."

Incyte's Jak inhibitor INCB-18424, a topical therapy with a novel mechanism of action, is expected to receive regulatory approval in the United States and Europe in 2013. The report finds that although INCB-18424 has demonstrated excellent efficacy in Phase II clinical trials, safety concerns and competition from lower priced brand and generic corticosteroids and vitamin D3 analogues will restrict sales of the agent through 2018.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan
2. New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements
3. Avid Bioservices Expands Executive Team as it Prepares for Continued Growth
4. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
5. Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide
6. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
7. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
8. DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth
9. On Third Anniversary, Compendia Bioscience Announces Continued Revenue Growth, Major Long-Term Customer Contracts and Forecasts Profitability
10. Nasdaq Panel Grants Advanced Life Sciences Request for Continued Listing on Nasdaq Stock Market
11. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):